Component
Human CSF acetylcarnitine concentration
Human CSF acetylcarnitine concentration
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Repeated ALCAR administration increased plasma and CSF ALCAR in an 11-patient Alzheimer pharmacokinetic study.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
- experimental_contrast
- {"intervention": "Sequential IV then oral ALCAR regimen", "comparator": "Run-in/sham period", "endpoint": "Repeated ALCAR administration increased plasma and CSF ALCAR in an 11-patient Alzheimer pharmacokinetic study.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- 1992 study with corrected indexed regimen: 30 mg/kg IV for 10 days followed by 1.5 g/day orally for 50 days.
- interpretation_status
- Source-derived curation with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
- plain_language
- Repeated ALCAR administration increased plasma and CSF ALCAR in an 11-patient Alzheimer pharmacokinetic study.
- primary_references
- Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. | https://pubmed.ncbi.nlm.nih.gov/1541322/ | https://doi.org/10.1007/bf00314926
- source_locator
- Reviewed reference human-csf; The indexed abstract includes corrected dosing and an erratum reference. CSF exposure is not cognitive efficacy or proof of intact labeled ALCAR reaching neuronal nuclei.
Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 104–110
AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · 1992 study with corrected indexed regimen: 30 mg/kg IV for 10 days followed by 1.5 g/day orally for 50 days. · Recorded from source · Recorded from source
### human-csf Repeated ALCAR administration increased plasma and CSF ALCAR in an 11-patient Alzheimer pharmacokinetic study. The indexed abstract includes corrected dosing and an erratum reference. CSF exposure is not cognitive efficacy or proof of intact labeled ALCAR reaching neuronal nuclei. Model and exposure: 1992 study with corrected indexed regimen: 30 mg/kg IV for 10 days followed by 1.5 g/day orally for 50 days. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. | 1992 | https://pubmed.ncbi.nlm.nih.gov/1541322/ | https://doi.org/10.1007/bf00314926 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.